Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (151-160 of 206) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|January 9, 2018
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapyGwamaka E Mwasakifwa, Cecilia Moore, Dianne Carey, et al.
AIDS (London, England)|April 20, 2002
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infectionKarin Loré, Anders Sönnerborg, Christina Broström, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2014
Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infectionEmma E Page, Louise Greathead, Rebecca Metcalf, et al.
The Journal of Infectious Diseases|September 20, 2005
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort studyColette J Smith, Andrew N Phillips, Teresa Hill, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2010
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair studyRebekah L Puls, Preeyaporn Srasuebkul, Kathy Petoumenos, et al.
The Journal of Infectious Diseases|May 10, 2002
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infectionJan Andersson, Sabine Kinloch, Anders Sönnerborg, et al.
HIV Medicine|March 14, 2007
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2, Zoe Fox, Francisco Antunes, et al.
AIDS Research and Human Retroviruses|March 19, 2009
Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudineRafael E Campo, Barbara A Da Silva, Laurent Cotte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2006
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysisAnton L Pozniak, Joel E Gallant, Edwin DeJesus, et al.
Plos One|November 3, 2012
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008Eduard J Beck, Sundhiya Mandalia, Roshni Sangha, et al.
Pageof 21

Showing results (151-160 of 206) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|January 9, 2018
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapyGwamaka E Mwasakifwa, Cecilia Moore, Dianne Carey, et al.
AIDS (London, England)|April 20, 2002
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infectionKarin Loré, Anders Sönnerborg, Christina Broström, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2014
Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infectionEmma E Page, Louise Greathead, Rebecca Metcalf, et al.
The Journal of Infectious Diseases|September 20, 2005
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort studyColette J Smith, Andrew N Phillips, Teresa Hill, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2010
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair studyRebekah L Puls, Preeyaporn Srasuebkul, Kathy Petoumenos, et al.
The Journal of Infectious Diseases|May 10, 2002
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infectionJan Andersson, Sabine Kinloch, Anders Sönnerborg, et al.
HIV Medicine|March 14, 2007
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2, Zoe Fox, Francisco Antunes, et al.
AIDS Research and Human Retroviruses|March 19, 2009
Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudineRafael E Campo, Barbara A Da Silva, Laurent Cotte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2006
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysisAnton L Pozniak, Joel E Gallant, Edwin DeJesus, et al.
Plos One|November 3, 2012
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008Eduard J Beck, Sundhiya Mandalia, Roshni Sangha, et al.
Pageof 21